A Phase II Trial of Erlotinib in Recurrent Squamous Cell Carcinoma of the Cervix
Open Access
- 1 July 2009
- journal article
- research article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 19 (5) , 929-933
- https://doi.org/10.1111/igc.0b013e3181a83467
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2009
- Erlotinib in Pancreatic Cancer: Are Tumor Cells the (only) Target?Journal of Clinical Oncology, 2007
- Cetuximab for the Treatment of Colorectal CancerNew England Journal of Medicine, 2007
- Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal CancerJournal of Clinical Oncology, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Analysis of chromosomes 3, 7, X and the EGFR gene in uterine cervical cancer progressionEuropean Journal Of Cancer, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Prolonged Oral Etoposide in Recurrent or Advanced Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group StudyGynecologic Oncology, 1998
- Expression of Epidermal Growth Factor Receptor in Carcinoma of the CervixGynecologic Oncology, 1996